Evidence map›Paper›PMID 40995370›Full record

ArticleFrontiers in immunology2025

Differential regulation of Treg stability in human naïve and effector Treg subsets by TGFβ-signaling via ARKADIA-SKI axis.

Fan Yang, Alexis Yanes, Miao Li, Patrick Heizer, Ivan Linatoc, Michael E Stephens, Yang Song, Tatiana Ort, Kyle J Bednar, Yasuhiro Ikeda and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fan YangBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Alexis YanesBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Miao LiBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Patrick HeizerBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Ivan LinatocBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Michael E StephensBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Yang SongBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Tatiana OrtBioscience Immunology, Research and Early Development, Respiratory and Immunology, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Kyle J BednarBioscience Immunology, Research and Early Development, Respiratory and Immunology, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Yasuhiro IkedaBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Zengli GuoBiologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The human FOXP3 Methods: Human naïve and effector Treg cells were isolated from healthy donors using flow cytometry. Different subsets of Treg cells were treated with a TGFβ inhibitor or genetically modified to express SKI or ARKADIA via lentiviral transduction. Treg cell phenotype, stability and signaling regulation were analyzed using flow cytometry, western blotting, transcriptomic and meta-analyses. The functionality of Treg cells was analyzed by Results: We find that the TGFβ signaling is differentially regulated in Treg subsets, with higher activity in the naïve Treg subset. Blockade of TGFβ pathway destabilizes both naïve and effector Treg cells, disrupting their immunosuppressive functions, with effector Treg cells being more susceptible. Further analysis shows that naïve Treg cells express lower levels of SKI protein, a negative regulator of TGFβ signaling suppressed by TGFβ-induced protein degradation. SKI overexpression destabilizes Treg cells and disrupts their immune suppressive function. Transcriptomic and meta-analyses reveal that TGFβ blockade and SKI overexpression commonly modulate pathways crucial for Treg to effector T cell conversion, downregulating Treg signature genes and upregulating effector T cell markers, which are validated as potential SKI targets. Importantly, overexpression of ARKADIA, an E3 ubiquitin ligase of SKI, efficiently reduces SKI levels, enhancing Treg cell stability and functionality under both TGFβ inhibition and chronic proinflammatory cytokine stimulation. Conclusion: Our results identify a previously unrecognized role of the TGFβ-ARKADIA-SKI axis in regulating the stability and functionality of human Treg subsets, highlighting novel strategies for harnessing TGFβ-associated pathways to stabilize human Treg cells for clinical applications.

Indexed as

DNA-Binding ProteinsProto-Oncogene ProteinsSignal TransductionT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsTransforming Growth Factor betaUbiquitin-Protein LigasesHumansDNA-Binding ProteinsProto-Oncogene ProteinsSKI protein, humanTransforming Growth Factor betaUbiquitin-Protein LigasesArkadiaautoimmunenaïve/effector Treg cellSkiTGFβTreg

Identifiers

PMID40995370
PMCPMC12454061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.